Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06059638 Recruiting - Hypertension Clinical Trials

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

BACKBEAT
Start date: December 27, 2023
Phase: N/A
Study type: Interventional

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic Astra/Azure DR MRI IPG.

NCT ID: NCT06052748 Recruiting - Clinical trials for Hypertension,Essential

A Study to Evaluate the Efficacy and Safety of AD-223

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AD-223

NCT ID: NCT06049862 Recruiting - Clinical trials for Primary Hypertension

The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial

"MaRiTensi"
Start date: October 11, 2023
Phase: N/A
Study type: Interventional

This study aims to know the effectiveness of "MaRiTensi" in improving knowledge, motivation, efficacy, self-care and blood pressure control for hypertension patients. This study hypothesizes that MaRiTensi effectively increases the knowledge, motivation, self-efficacy and self-care of hypertensive patients and reduces blood pressure in the intervention group compared to the control group. Respondent recruitment is as follows: 1. The respondent candidate will be identified based on data on record medical 2. Appropriate respondent candidates' criteria inclusion and exclusion contacted for given informed consent 3. Prospective respondents who are willing to participate and fulfill the criteria for pressure blood moment measurement will request signed consent 4. Respondents fill in the basic data and recapitulate by the assistant researcher 5. Done randomization for allocation of group interventions and group control 6. Respondents given envelope closed (using sequentially numbered, opaque sealed envelopes (SNOSE) method ) 7. Respondents' group intervention was given maintenance by Hospital or health center standard-added intervention using MaRiTensi by conditions; meanwhile, group control was provided care by Hospital or health center standards.

NCT ID: NCT06019598 Recruiting - Clinical trials for Hypertension,Essential

Licorice and Home Blood Pressure, Additional Study

Start date: September 10, 2023
Phase: N/A
Study type: Interventional

Out-of-office blood pressure is more strongly associated with cardiovascular risk than office blood pressure. Licorice is known to raise blood pressure, but no previous studies have measured the effects on home blood pressure. The aim of this study is to analyze the association between licorice intake and home blood pressure.

NCT ID: NCT06018493 Recruiting - Hypertension Clinical Trials

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

NCT ID: NCT05947448 Recruiting - Clinical trials for Essential Hypertension

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Start date: January 22, 2024
Phase:
Study type: Observational [Patient Registry]

This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: AZL-M monotherapy group, CCB monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. Subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected

NCT ID: NCT05931224 Recruiting - Clinical trials for Essential Hypertension

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

Start date: June 28, 2023
Phase: Phase 3
Study type: Interventional

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

NCT ID: NCT05930028 Recruiting - Clinical trials for Essential Hypertension

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Start date: July 13, 2023
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

NCT ID: NCT05910242 Recruiting - Clinical trials for Essential Hypertension

Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.

NCT ID: NCT05900713 Recruiting - Clinical trials for Essential Hypertension

Effect of DNS Exercises Training on Hypertension

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Purpose of the study This study will be conducted to investigate any significant effect of dynamic neuromuscular stabilization training on postural control in patients with essential hypertension.